{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:58:39Z","timestamp":1790470719454,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1136\/ijgc-2019-000211","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T12:37:09Z","timestamp":1555418229000},"page":"768-771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients"],"prefix":"10.1016","volume":"29","author":[{"given":"Francesco","family":"Plotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Schir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Terranova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"De Cicco Nardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Montera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Luvero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Scaletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Capriglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Benedetti Panici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Angioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2019-000211_bb0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2019-000211_bb0015","unstructured":"National Comprehensive Cancer Network (NCCN.org) Ovarian Cancer, version 1.2017 ."},{"issue":"10 Suppl","key":"10.1136\/ijgc-2019-000211_bb0020","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G","article-title":"Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers","volume":"76","author":"Skates","year":"1995","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2019-000211_bb0025","first-page":"1","article-title":"Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames ovary group study. CA125 tumor-associated antigen: a review of the literature","volume":"4","author":"Rustin","year":"1989","journal-title":"Hum Rep"},{"key":"10.1136\/ijgc-2019-000211_bb0030","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000217982","article-title":"Specificity and affinity of 26 monoclonal antibodies against the Ca 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine","volume":"17","author":"Nustad","year":"1996","journal-title":"Tumour Biol"},{"key":"10.1136\/ijgc-2019-000211_bb0035","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1006\/gyno.2002.6689","article-title":"Specific keynote: ovarian cancer risk assessment and the potential for early detection","volume":"88","author":"Urban","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-000211_bb0040","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1515\/cclm-2013-0151","article-title":"Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis","volume":"51","author":"Bandiera","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"10.1136\/ijgc-2019-000211_bb0045","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-000211_bb0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2019-000211_bb0055","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2019-000211_bb0060","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14737140.2017.1360138","article-title":"The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review","volume":"17","author":"Scaletta","year":"2017","journal-title":"Expert Review of Anticancer Therapy"},{"key":"10.1136\/ijgc-2019-000211_bb0065","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1007\/s13277-014-1836-x","article-title":"Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?","volume":"35","author":"Angioli","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1136\/ijgc-2019-000211_bb0070","first-page":"161","article-title":"Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1136\/ijgc-2019-000211_bb0075","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1136\/ijgc-2019-000211_bb0080","doi-asserted-by":"crossref","DOI":"10.1186\/1757-2215-5-11","article-title":"The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study","volume":"5","author":"Varughese","year":"2012","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2019-000211_bb0085","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s13277-012-0471-7","article-title":"Does HE4 have a role as biomarker in the recurrence of ovarian cancer?","volume":"33","author":"Plotti","year":"2012","journal-title":"Tumour Biol"},{"key":"10.1136\/ijgc-2019-000211_bb0090","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","article-title":"Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence","volume":"110","author":"Havrilesky","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-000211_bb0095","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/cncr.25203","article-title":"CA 125 and the detection of recurrent ovarian cancer","volume":"116","author":"Bast","year":"2010","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2019-000211_bb0100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol"},{"key":"10.1136\/ijgc-2019-000211_bb0105","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.3892\/or.2013.2682","article-title":"Serum HE4 levels combined with Ce CT imaging improve the management of monitoring women affected by epithelial ovarian cancer","volume":"30","author":"Manganaro","year":"2013","journal-title":"Oncol Rep"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2401140X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2401140X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2019-000211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:37:20Z","timestamp":1753223840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2401140X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1048891X2401140X"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2019-000211","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2019-000211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}